# SECTION F: 510(k) Summary

# 510(k) SUMMARY

This summary of safety and effectiveness information is submitted in compliance with 21CFR807.92.

1. Application Date: December 29, 2006

2. Applicant Information: Polymer Technology Systems, Inc. 7736 Zionsville Road Indianapolis, IN 46268

Contact Person: Margo Enright Phone Number: 317-870-5610 FAX Number: 317-870-5608 e-mail: menright@cardiochek.com

3. Trade Name: PTS PANELS Metabolic Chemistry Panel Test Strips

4. Classification Names: Common Name(s): Glucose Test System, Lipoprotein and cholesterol (high density lipoprotein) test systems, Triglyceride Test System Panel: Clinical Chemistry 75 Product Codes: NBW, NAQ, NGO

5. Facility Address: 7736 Zionsville Road Indianapolis, IN 46268

6. Device Classification: Class 2 (Regulations: 21 CFR 862.1345, 862.1175, 862.1475, 862.1705)

# 7. Intended Use:

PTS PANELS Metabolic Chemistry Panel Test Strips are intended to be used by medical professionals and individuals in the home to measure glucose, high density lipoprotein cholesterol and triglycerides in fingerstick whole blood. Glucose measurements are used in the management of carbohydrate metabolism disorders. Cholesterol measurements are used in the diagnosis and treatment of disorders involving excess cholesterol in the blood and lipid and lipoprotein metabolism disorders. Lipoprotein measurements are used in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases. Triglycerides measurements are used in the diagnosis and treatment of patients with diabetes mellitus, nephrosis, liver obstruction, other diseases involving lipid metabolism, or various endocrine disorders.

8. Reason for $\mathbf { 5 1 0 ( k ) }$ : Device Modification

9. Predicate Device Information The predicate devices for determination of substantial equivalence are: Name: PTS PANELS Glucose, HDL Cholesterol and Triglycerides Test Strips

# Similarities and Differences between modified device (PTS PANELS Metabolic Chemistry Test Strips) and the Predicate Device (unmodified- PTS PANELS Glucose, HDL Cholesterol and Triglycerides Test Strips)

Similarities Between Predicate and Modified Device   

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Predicates</td><td rowspan=1 colspan=1>Modified Device</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Intended to measure glucose,HDL cholesterol andtriglycerides in whole blood.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Technology</td><td rowspan=1 colspan=1>Dry chemistry test strip for usewith PTS reflectancephotometer.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>ProductStorage</td><td rowspan=1 colspan=1>Store with vial tightly capped ina cool dry place at roomtemperature of 68-86Â°F.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Specimen</td><td rowspan=1 colspan=1>Whole blood from fingerstickor venous blood collected in anEDTA or heparin tube.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>ChemistryMethod</td><td rowspan=1 colspan=1>Glucose: Colorimetricenzymatic (glucose oxidase)HDL: Colorimetric enzymatic(cholesterol esterase/oxidase)trinder method for cholesterol.Triglycerides: Colorimetricenzymatic (cholesterol esterase/glycerophosphate oxidase)</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>CalibrationCurve</td><td rowspan=1 colspan=1>Resides on a read-only memory(EEPROM) chip packaged withthe test strips.</td><td rowspan=1 colspan=1>Same</td></tr></table>

Differences Between Predicate and Modified Device   

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Predicates</td><td rowspan=1 colspan=1>Modified Device</td></tr><tr><td rowspan=1 colspan=1>Number oftest strips toobtain results</td><td rowspan=1 colspan=1>Three separate test strips</td><td rowspan=1 colspan=1>Single test strip withthree tests</td></tr><tr><td rowspan=1 colspan=1>Time toobtain results</td><td rowspan=1 colspan=1>About one minute for each test.</td><td rowspan=1 colspan=1>About two minutesfor all three testresults.</td></tr></table>

# 10. Compliance with Special Controls

Does not apply.

Margo Enright   
Polymer Technology Systems, Inc. 7736 Zionsville Road   
Indianapolis, IN 46268

Re: k070017 Trade/Device Name: PTS Panels Metabolic Chemistry Panel Test Strips Regulation Number: 21 CFR $\ S$ 862.1345 Regulation Name: Glucose test system Regulatory Class: Class II Product Code: NBW, CGA, JGY, LBR, NAQ, NGO Dated: December 29, 2006 Received: January 03, 2007

Dear Ms. Enright:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices hat have beelassi  dnce wihhe proisons  the Federal FdDru and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class II (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0490. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address at   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Jean M.COopers, M.S. D.V.M. Jean M. Cooper, M.S., D.V.M.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and   
Radiological Health

# Indications for Use

Device Name: PTS PANELS Metabolic Chemistry Panel Test Strips

PTS PANELS Metabolic Chemistry Panel Test Strips are intended to be used by medical professionals and individuals in the home to measure glucose, high density lipoprotein cholesterol and triglycerides in fingerstick whole blood. Glucose measurements are used in the management of carbohydrate metabolism disorders. Cholesterol measurements are used in the diagnosis and treatment of disorders involving excess cholesterol in the blood and lipid and lipoprotein metabolism disorders. Lipoprotein measurements are used in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases. Triglycerides measurements are used in the diagnosis and treatment of patients with diabetes mellitus, nephrosis, liver obstruction, other diseases involving lipid metabolism, or various endocrine disorders.

Caof CBeniam fice of In Vitro Diagnostic Device " aluation and Safety

Page 1 of

K070017